Statements (13)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:company
|
gptkbp:clinicalTrialPhase |
Phase II
|
gptkbp:developedBy |
Prolong Pharmaceuticals
|
https://www.w3.org/2000/01/rdf-schema#label |
Sanguinate
|
gptkbp:industry |
gptkb:biotechnology
|
gptkbp:intendedUse |
treatment of anemia
treatment of sickle cell disease |
gptkbp:mechanismOfAction |
oxygen transfer agent
|
gptkbp:productType |
oxygen therapeutic
|
gptkbp:routeOfAdministration |
intravenous
|
gptkbp:status |
investigational drug
|
gptkbp:bfsParent |
gptkb:Artificial_Blood
|
gptkbp:bfsLayer |
8
|